Sotorasib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 596 publications

Standard Versus Reduced Sotorasib Dosing in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis-Have We Answered the Dosing Question?

Standard Versus Reduced Sotorasib Dosing in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis-Have We Answered the Dosing Question?

Journal: JCO oncology practice
Published: June 01, 2026

mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion.

mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion.

Journal: bioRxiv : the preprint server for biology
Published: May 13, 2026

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition.

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition.

Journal: bioRxiv : the preprint server for biology
Published: May 07, 2026

Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib.

Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib.

Journal: JCO precision oncology
Published: May 06, 2026

Immunohistochemical Localization of Sotorasib-Protein Conjugates in the Rat Gastrointestinal Tract.

Immunohistochemical Localization of Sotorasib-Protein Conjugates in the Rat Gastrointestinal Tract.

Journal: Biological & pharmaceutical bulletin
Published: April 20, 2026

Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.

Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.

Journal: Expert opinion on drug discovery
Published: April 20, 2026

Galangin Overcomes Gefitinib and Sotorasib Resistance in Non-small Cell Lung Cancer by Inhibiting Efferocytosis.

Galangin Overcomes Gefitinib and Sotorasib Resistance in Non-small Cell Lung Cancer by Inhibiting Efferocytosis.

Journal: Journal of agricultural and food chemistry
Published: April 20, 2026

Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.

Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 15, 2026

Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.

Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.

Journal: Cancers
Published: April 10, 2026

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.

Journal: Cancer treatment reviews
Published: March 21, 2026

Clinical characteristics of 20 lung adenocarcinoma patients misdiagnosed as interstitial pneumonia

Clinical characteristics of 20 lung adenocarcinoma patients misdiagnosed as interstitial pneumonia

Journal: Zhonghua yi xue za zhi
Published: March 19, 2026

Sotorasib induces intestinal epithelial injury through suppression of the cAMP/PKA/CREB signaling axis.

Sotorasib induces intestinal epithelial injury through suppression of the cAMP/PKA/CREB signaling axis.

Journal: Biochemical pharmacology
Published: March 18, 2026
Showing 1-12 of 596

Last Updated: 06/30/2026